FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

Emergent inks $29.7M anthrax vax contract

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools

Emergent BioSolutions has inked a three-year, $29.7 million deal with Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID). BARDA/NIAID will fund the further development of AV7909, a an anthrax vaccine candidate. AV7909 is made up of Emergent's own BioThrax and CPG 7909 (VaxImmune), which it licensed from Pfizer.

The three-year contract provides up to $24.9 million of funding for manufacturing of clinical lots, for non-clinical safety and efficacy studies, and for stability studies to further demonstrate that the vaccine candidate does not need refrigeration during storage, a key requirement of this vaccine development initiative. In addition, the contract provides up to $4.8 million for a Phase I clinical trial, to be funded as an option that, if exercised, would increase the value of the contract to $29.7 million.

- see Emergent's release

Related Articles:
Emergent wins $24M anthrax contract
Emergent accuses biotech execs of wrecking buyout pact
VaxGen sells anthrax vaccine to Emergent


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about Vaccine   anthrax   Emergent BioSolutions   NIAID   AV7909